Treatment of behavioral and psychological symptoms of Alzheimer's disease

Current Treatment Options in Neurology

Volumn 14, Issue 2, 2012, Pages 113-125

  Corbett, Anne ^b   Smith, Jessica ^b   Creese, Byron ^a   Ballard, Clive ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b ALZHEIMER'S SOCIETY   (United Kingdom)

Author keywords

Aggression; Agitation; Alzheimer's disease; Assessment; Atypical antipsychotics; BPSD; Infection; Pain; Person centered care; Psychological interventions; Psychosis; Risperidone; Staff training; Symptoms; Treatment

Indexed keywords

ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CARBAMAZEPINE; CHOLINESTERASE INHIBITOR; CITALOPRAM; DONEPEZIL; HALOPERIDOL; MEMANTINE; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; PRAZOSIN; PROMAZINE; QUETIAPINE; RISPERIDONE; THIORIDAZINE; TIOTIXENE; VALPROIC ACID; XANOMELINE;

AGGRESSION; ALZHEIMER DISEASE; ANXIETY DISORDER; BEHAVIOR DISORDER; BIPOLAR DISORDER; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CHEST INFECTION; COGNITIVE DEFECT; COGNITIVE THERAPY; DEHYDRATION; DELIRIUM; DELUSION; DEPRESSION; DRUG EFFICACY; DRUG FATALITY; DYSPHORIA; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; FALLING; GAIT DISORDER; GASTROINTESTINAL SYMPTOM; HEART ARRHYTHMIA; HUMAN; HYPOTENSION; MENTAL DISEASE; META ANALYSIS (TOPIC); PARKINSONISM; PERIPHERAL EDEMA; PRESCRIPTION; PSYCHOSIS; PSYCHOSOCIAL CARE; PSYCHOTHERAPY; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY TRACT INFECTION; REVIEW; SCHIZOPHRENIA; SIDE EFFECT; SOMNOLENCE; TARDIVE DYSKINESIA; URINARY TRACT INFECTION;

EID: 84862792198     PISSN: 10928480     EISSN: 15343138     Source Type: Journal    
DOI: 10.1007/s11940-012-0166-9     Document Type: Review

References (62)

1. Alzheimer's Disease International Fact Sheet: The prevalence of dementia worldwide. December 2008. Available at www.alz.co.uk/adi/pdf/prevalence.pdf.
2. Steinberg M, Shao H, Zandi P, et al. Point and 5-year period prevalence of neuropsychiatric symptoms in dementia: the Cache County Study. Int J Geriatr Psychiatry. 2008;23:170-7. (Pubitemid 351308497)
3. Burns A, Jacoby R, Levy R. Psychiatric phenomena in Alzheimer's disease. IV: disorders of behaviour. Br J Psych. 1990;157:86-94. (Pubitemid 20208666)
4. Lyketsos CG, Steinberg M, Tschanz JT, Norton MC, Steffens DC, Breitner JC. Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging. Am J Psych. 2000;157:708-14. (Pubitemid 30249648)
5. Margallo-Lana M, Swann A, O'Brien J, et al. Prevalence and pharmacological management of behavioural and psychological symptoms amongst dementia sufferers living in care environments. Int J Geriatric Psych. 2001;16:39-44. (Pubitemid 32111815)
6. Lyketsos CG. Neuropsychiatric symptoms (behavioral and psychological symptoms of dementia) and the development of dementia treatments. Int Psychogeriatr. 2007;19:409-20. (Pubitemid 46707421)
7. Gilley DW, Whalen ME, Wilson RS, Bennett DA. Hallucinations and associated factors in Alzheimer's disease. J Neuropsych & Clin Neurosci. 1991;3:371-6.
8. Rabins PV, Mace NL, Lucas MJ. The impact of dementia on the family. JAMA. 1982;248:333-5. (Pubitemid 12070768)
9. Ballard CG, Patel A, Solis M, Lowe K, Wilcock G. A follow up study of depression in the carers of dementia sufferers. BMJ. 1996;312:947. (Pubitemid 26111786)
10. Banerjee S, Smith SC, Lamping DL, et al. Quality of life in dementia: more than just cognition. An analysis of associations with quality of life in dementia. J Neurol, Neurosurg Psych. 2006;77:146-8. (Pubitemid 43220831)
11. Steele C, Rovner B, Chase GA, Folstein M. Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease. Am J Psych. 1990;147:1049-51. (Pubitemid 20257519)
12. Holroyd S, Laurie S. Correlates of psychotic symptoms among elderly outpatients. Int J Geriatric Psych. 1999;14:379-84. (Pubitemid 29271529)
13. Chapman FM, Dickinson J, McKeith I, Ballard C. Association among visual hallucinations, visual acuity, and specific eye pathologies in Alzheimer's disease: treatment implications. Am J Psych. 1999;156:1983-5.
14. Cohen-Mansfield J, Lipson S. The utility of pain assessment for analgesic use in persons with dementia. Pain. 2008;134:16-23. (Pubitemid 350251001)
15. Husebo B, Ballard C, Sandvik R, Nilsen OB, Aarsland D. Efficacy of treating pain to reduce behavioural disturbances in residents of nursing homes with dementia: cluster randomised clinical trial. BMJ. 2011;343:d4065 (Class B evidence). This novel cluster RCT in 60 nursing home units demonstrates the value of stepped analgesia in significantly improving agitation and pain, in comparison to usual care over 8 weeks.
16. Lyketsos CG, Colenda CC, Beck C, et al. Position statement of the American Association for Geriatric Psychiatry regarding principles of care for patients with dementia due to Alzheimer disease. Am J Geriatr Psych. 2006;14:561-72. (Pubitemid 44036480)
17. Cohen-Mansfield J, Libin A, Marx MS. Nonpharmacological treatment of agitation: a controlled trial of systematic individualized intervention. J Gerontol A Biol Sci Med Sci. 2007;62:908-16 (Class B evidence). (Pubitemid 350139005)
18. Cohen-Mansfield J, Werner P. Management of verbally disruptive behaviors in nursing home residents. J Gerontol Series A-Biol Sci Med Sci. 1997;52:369-77 (Class B evidence).
19. Ballard C, Brown R, Fossey J, et al. Brief psychosocial therapy for the treatment of agitation in alzheimer disease (The CALM-AD Trial). Am J Geriatr Psychiatr. 2009;17:726-33 (Class C evidence).
20. Bird M. Psychosocial approaches to challenging behaviour in dementia: a controlled trial. In: Report to the Commonwealth Department of Health and Ageing. Canberra: Office for Older Australians 2002. (Class B evidence).
21. Fossey J, Ballard C, Juszczak E, et al. Effect of enhanced psychosocial care on antipsychotic use in nursing home residents with severe dementia: cluster randomised trial. BMJ. 2006;332:756-8 (Class B evidence). (Pubitemid 44365651)
22. Ballard C, Powell I, James I, et al. Can psychiatric liaison reduce neuroleptic use and reduce health service utilization for dementia patients residing in care facilities. Int J Geriatric Psych. 2002;17:140-5. (Pubitemid 34130304)
23. Chenoweth L, King MT, Jeon YH, et al. Caring for Aged Dementia Care Resident Study (CADRES) of person-centred care, dementia-care mapping, and usual care in dementia: a cluster-randomised trial. Lancet Neurol. 2009;8:317-25. (Class B evidence). This large cluster RCT demonstrates significant improvements in agitation with person-centered care training and Dementia Care Mapping in comparison to usual care over 4 months.
24. The Use of Antipsychotic medication for people with dementia: Time for Action. A report For the Minister of State for Care Services by Professor Sube Banerjee, 2009. www.dh.gov. uk/prod-consum-dh/groups/dh-digitalassets/documents/ digitalasset/dh-108302.pdf.
25. Deaths with antipsychotics in elderly patients with behavioral disturbances. U. S. Food and Drug Administration, FDA Public Health Advisory, Centre for Drug Evaluation and Research. FDA 13-7-2005.
26. Information for Healthcare Professionals: Conventional Antipsychotics FDA ALERT [6/16/2008] www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm124830.htm.
27. Ballard C, Howard R. Neuroleptic drugs in dementia: benefits and harm. Nat Rev Neurosci. 2006;7:492-500 (Class A evidence). (Pubitemid 44012289)
28. Tune LE, Steele C, Cooper T. Neuroleptic drugs in the management of behavioral symptoms of Alzheimer's disease. Psych Clinics North America. 1991;14:353-73 (Class C evidence).
29. Reilly JG, Ayis SA, Ferrier IN, Jones SJ, Thomas SHL. QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet. 2000;355:1048-52 (Class C evidence). (Pubitemid 30162807)
30. Hollis J, Grayson D, Forrester L, Brodaty H, Touyz S, Cumming R. Antipsychotic medication dispensing and risk of death in veterans and war widows 65 years and older. Am J Geriatric Psych 2007;932-41. (Class C evidence).
31. Wang PS, Schneeweiss S, Avorn J, Fischer MA, et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. New Engl J Med. 2005;353:2335-41 (Class C evidence). (Pubitemid 41713745)
32. Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatric Psych. 2006;14:191-210 (Class A evidence).
33. Zhong KX, Tariot PN, Mintzer J, Minkwitz MC, Devine NA, et al. Quetiapine to treat agitation in dementia: a randomized double-blind placebo controlled study. Curr Alzheimer Res. 2007;4:81-93 (Class B evidence). (Pubitemid 46293886)
34. Mintzer JE, Tune LE, Breder CD, et al. Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses. Am J Geriatric Psych. 2007;15:918-31 (Class B evidence).
35. Ballard C, Margallo-Lana M, Juszczak E, et al. Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomized double blind placebo controlled trial. BMJ. 2005;330:874 (Class B evidence).
36. Ballard C, Lana MM, Theodoulou M, et al. Investigators DART AD. A randomized, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (the DART-AD trial). PLoS Medicine/Public Library of Science. 2008;5:76 (Class B evidence).
37. Schneider LS, Tariot PN, Dagerman KS, et al. CATIE-AD Study Group. Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. New Engl J Med. 2006;355:1525-3830 (Class B evidence).
38. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA. 2005;294:1934-43 (Class A evidence). (Pubitemid 41464695)
39. Ballard C, Hanney ML, Theodoulou M, et al. DARTAD investigators. The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomized placebo-controlled trial. Lancet Neurol. 2009;8:151-7. (Class A evidence). This 12-month RCT with longer-term open follow-up demonstrated that the increased mortality risk associated with antipsychotics in people with Alzheimer's disease persists over longer periods of treatment.
40. Angelucci F, Bernadini S, Gravina P, et al. Délusion symptômes and réponse to antipsychotic treatment are associâtes with the 5-HT2A receptor polymorphism (102T/C) in Alzheimer's diseases: a 3-year follow-up longitudinal study. J Alzheim Dis. 2009;17:203-11 (Class C evidence).
41. Dombrovski AY, Mulsant BH, Ferrell RE, et al. Serotonin transporter triallelic genotype and response to citalopram and risperidone in dementia with behavioral symptoms. Int Clin Psychopharmacol. 2010;25(1):37-45 (Class B evidence).
42. Trinh NH, Hoblyn J, Mohanty S, Yaffe K. Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. JAMA. 2003;289:210-6 (Class A evidence). (Pubitemid 36068709)
43. Holmes C, Wilkinson D, Dean C, et al. The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease. Neurol. 2004;63:214-9 (Class B evidence). (Pubitemid 38971117)
44. Howard RJ, Juszczak E, Ballard C, et al. Donepezil for the treatment of agitation in Alzheimer's disease. N Engl J Med. 2007;357:1382-92 (Class B evidence). (Pubitemid 47535593)
45. Gauthier S, Feldman H, Hecker J, et al. Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer's disease. Int Psychogeriatr. 2002;14:389-404 (Class B evidence). (Pubitemid 36331605)
46. Gauthier S, Wirth Y, Mobius HJ. Effects of memantine on behavioural symptoms in Alzheimer's disease patients: an analysis of the Neuropsychiatric Inventory (NPI) data of two randomised, controlled studies. Int J Geriatr Psych. 2005;20:459-64 (Class B evidence). (Pubitemid 40716339)
47. McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database Syst Rev Issue 2. 2006. Art. No.: CD003154. (Class A evidence).
48. Gauthier S, Loft H, Cummings J. Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis. Int J Geriatr Psych. 2008;23:537-45 (Class B evidence). (Pubitemid 351722115)
49. Wilcock GK, Ballard CG, Cooper JA, Loft H. Memantine for agitation/aggression and psychosis in moderately severe to severe Alzheimer's disease: a pooled analysis of 3 studies. J Clin Psych. 2008;69:341-8 (Class B evidence). (Pubitemid 351549385)
50. Pollock BG, Mulsant BH, Rosen J, et al. Comparison of citalopram, perphenazine, and placebo for the acute treatment of psychosis and behavioral disturbances in hospitalized, demented patients. Am J Psych. 2002;159:460-5 (Class B evidence). (Pubitemid 34184743)
51. Pollock BG, Mulsant BH, Rosen J, et al. A doubleblind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia. Am J Geriatr Psych. 2007;15:942-52 (Class B evidence).
52. Finkel SI, Mintzer JE, Dysken M, Krishnan KRR, Burt T, McRae T. A randomized, placebo-controlled study of the efficacy and safety of sertraline in the treatment of the behavioral manifestations of Alzheimer's disease in outpatients treated with donepezil. Int J Geriatr Psych. 2004;19:9-18 (Class B evidence). (Pubitemid 38180687)
53. Teri L, Logsdon RG, Peskind E, et al. Treatment of agitation in AD: a randomized, placebo-controlled clinical trial. Neurol. 2000;55:1271-8 (Class B evidence).
54. Tariot PN, Erb R, Podgorski CA, et al. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. Am J Psych. 1998;155:54-61 (Class B evidence). (Pubitemid 28037549)
55. Olin JT, Fox LS, Pawluczyk S, Taggart NA, Schneider LS. A pilot randomized trial of carbamazepine for behavioral symptoms in treatment-resistant outpatients with Alzheimer disease. Am J Geriatr Psych. 2001;9:400-5 (Class B evidence). (Pubitemid 33015127)
56. Ballard CG, Gauthier S, Cummings JL, et al. Management of agitation and aggression associated with Alzheimer disease. Nat Rev Neurosci. 2009;5:245-55 (Class A evidence).
57. Konovalov S, Muralee S, Tampi RR. Anticonvulsants for the treatment of behavioral and psychological symptoms of dementia: a literature review. Int Psychogeriatr. 2008;20:293-308 (Class A evidence). (Pubitemid 351230232)
58. Ballard C, Piggott M, Johnson M, et al. Delusions associated with elevated muscarinic binding in dementia with Lewy bodies. Annals of Neurol. 2000;48:868-76.
59. Bodick NC, Offen WW, Levey AI, et al. Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease. Arch Neurol. 1997;54:465-73 (Class B evidence). (Pubitemid 27172867)
60. Sharp SI, Ballard CG, Chen CP, Francis PT. Aggressive behavior and neuroleptic medication are associated with increased number of alpha1-adrenoceptors in patients with Alzheimer disease. Am J Geriatric Psych. 2007;15:435-7.
61. Wang LY, Shofer JB, Rohde K, et al. Prazosin for the treatment of behavioral symptoms in patients with Alzheimer disease with agitation and aggression. Am J Geriatr Psychiatr. 2009;17:744-51. (Class B evidence). This small but interesting preliminary RCT highlights prazosin as a potential novel treatment for BPSD.
62. www.alzheimers.org.uk/bpsdguide. Accessed 30 Nov. 2011.